南新制药(688189) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥111,835,236.68, representing a decrease of 63.12% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2024 was ¥3,766,508.55, down 69.95% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,292,851.63, a decline of 79.62% compared to the previous year[5]. - The basic earnings per share for Q1 2024 was ¥0.0137, reflecting a decrease of 70.02% year-on-year[5]. - Net profit for Q1 2024 was ¥4,677,245.81, a decline of 67.4% from ¥14,364,549.60 in Q1 2023[19]. - Operating profit for Q1 2024 was ¥4,554,127.43, down 75.5% from ¥18,595,451.64 in Q1 2023[19]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.0137, compared to ¥0.0457 in Q1 2023[20]. Cash Flow - The net cash flow from operating activities was ¥36,863,557.07, an increase of 1,280.20% compared to the same period last year[5]. - Cash flow from operating activities for Q1 2024 was ¥36,863,557.07, an increase from ¥2,670,878.86 in Q1 2023[22]. - The company reported a net cash decrease of ¥18,419,625.64 in Q1 2024, contrasting with an increase of ¥43,681,456.52 in Q1 2023[23]. - Total cash outflow from financing activities in Q1 2024 was ¥47,973,027.73, compared to ¥11,800,772.25 in Q1 2023[22]. - Cash and cash equivalents at the end of Q1 2024 were ¥543,309,757.82, down from ¥757,153,421.15 at the end of Q1 2023[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,695,297,794.00, down 2.43% from the end of the previous year[6]. - As of March 31, 2024, the total current assets amounted to RMB 1,245,613,160.93, a decrease from RMB 1,290,011,027.37 as of December 31, 2023, reflecting a decline of approximately 3.5%[14]. - The company's cash and cash equivalents were RMB 644,597,429.05, down from RMB 665,760,897.54, indicating a decrease of about 3.3%[13]. - Accounts receivable stood at RMB 522,624,553.81, a slight decrease from RMB 543,961,786.48, representing a decline of approximately 3.9%[13]. - The total liabilities decreased to RMB 396,291,492.81 from RMB 435,210,026.70, marking a reduction of about 8.9%[15]. - The total assets as of March 31, 2024, were RMB 1,695,297,794.00, down from RMB 1,737,536,466.45, reflecting a decrease of approximately 2.4%[15]. - The company's non-current assets totaled RMB 449,684,633.07, slightly up from RMB 447,525,439.08, indicating a marginal increase of about 0.5%[14]. - The total equity attributable to shareholders decreased to RMB 1,313,885,150.78 from RMB 1,318,116,026.60, a decline of approximately 0.3%[15]. Research and Development - Research and development expenses totaled ¥16,512,853.64, a decrease of 51.46% year-on-year, while the R&D expense ratio to operating revenue increased by 3.55 percentage points to 14.77%[6]. - Research and development expenses for Q1 2024 were ¥6,826,875.34, significantly reduced from ¥34,015,766.79 in Q1 2023[18]. Market Strategy - The company adjusted its sales strategy in response to market conditions, leading to a decline in sales prices of some core products, which contributed to the decrease in revenue[8]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,051[10].